Tobacco and coffee contain bioactive compounds that may reduce Parkinson's disease risk by targeting key pathways such as MAO ...

Am J Health Syst Pharm. 2006;63(10):915-928. Results of this study suggest that adjunctive rasagiline significantly reduces off time with efficacy similar to that observed by adding entacapone to ...

Concizumab-mtci (Alhemo) is approved for hemophilia A or B with inhibitors, offering a subcutaneous alternative to intravenous treatments. The phase 3 explorer7 trial demonstrated an 86% reduction ...

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce bleeding episodes in patients aged 12 and older. The FDA recently approved ...

State Key Laboratory of Natural and Biomimetic Drugs and Department of Pharmaceutical Analysis, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China State Key Laboratory of ...

The participants were on stable levodopa or monoamine oxidase-B inhibitor monotherapy for more than three months before enrollment. Study participants received prasinezumab or placebo every 4 weeks ...

These next-generation STAT6 inhibitors demonstrate excellent oral bioavailability, cell permeability, and metabolic stability, and do not target STAT6 for degradation. DeepCure expects to select a ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson's ...

double-blind trial evaluating the efficacy and safety of prasinezumab compared with placebo in 586 randomised patients with early-stage Parkinson's disease who were on stable symptomatic treatment ...